Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753889 | 1.00 | BIRC2 (0.36) | BIRC2 | |
| SCHEMBL14034127 | 0.75 | — | — | |
| SCHEMBL16440917 | 0.75 | MAPT (0.45) | — | |
| SCHEMBL13935157 | 0.74 | — | — | |
| SCHEMBL405690 | 0.69 | — | — | |
| SCHEMBL30605761 | 0.67 | — | — | |
| SCHEMBL13014352 | 0.67 | CA2 (0.31) | — | |
| SCHEMBL18779683 | 0.66 | — | — | |
| SCHEMBL14415939 | 0.65 | — | — | |
| SCHEMBL82072 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367674-B2 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | WU WENXUE | 2010-09-30 | — | — | US | disclosed |
| US-7745626-B2 | Stereoselective alkylation of chiral 2-methyl-4-protected piperazines | SCHERING CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100120786-A1 | Piperazine Derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090270336-A1 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270336-A1 | Piperazine derivatives | CCR5, CCR2, CXCR3 | BIRC2 322/4885 |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | BIRC2 3385/4885 |
| US-20100120786-A1 | Piperazine Derivatives | CCR5, CCR2, CXCR3 | BIRC2 322/4885 |
| US-20100249411-A1 | Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines | ALKBH5, AZI2, PNMT | BIRC2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.